ImmunityBio, Inc.·4

Feb 24, 8:05 PM ET

Selecky Christobel 4

4 · ImmunityBio, Inc. · Filed Feb 24, 2026

Insider Transaction Report

Form 4
Period: 2026-02-23
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-23$2.98/sh+25,000$74,50025,000 total
  • Sale

    Common Stock

    [F1]
    2026-02-23$10.00/sh25,000$250,0000 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F2]
    2026-02-2325,00067,937 total
    Exercise: $2.98Exp: 2032-06-14Common Stock (25,000 underlying)
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
  • [F2]One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.
Signature
/s/ Philip LoScalzo, as Attorney-in-Fact|2026-02-24

Documents

1 file
  • 4
    wk-form4_1771981555.xmlPrimary

    FORM 4